Triazolam-D4 is a deuterated derivative of triazolam, a medication primarily used for the short-term treatment of insomnia. As a benzodiazepine, triazolam acts on the central nervous system, enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) to produce sedative and anxiolytic effects. The "D4" designation indicates that four hydrogen atoms in the molecule have been replaced with deuterium, a stable isotope of hydrogen. This modification is often used in research to trace the compound's behavior in biological systems or to study its pharmacokinetics without altering its pharmacological properties significantly. Triazolam-D4 retains the core structure of triazolam, which includes a triazole ring and a benzodiazepine framework, contributing to its activity. The compound is typically utilized in scientific studies rather than clinical applications, providing insights into the metabolism and effects of triazolam in various environments. As with all benzodiazepines, careful consideration of dosage and potential for dependence is essential in any context involving its use.

TRIAZOLAM-D4

145225-04-3: 4H-1,2,4Triazolo4,3-a1,4benzodiazepine, 8-chloro-6-(6-chlorophenyl-2,3,4,5-d4)-1-methyl-

CAS 145225-04-3: TRIAZOLAM-D4

Triazolam-D4 0.1 mg/ml in Methanol

Ref: TR-LGCAMP1363.80-02